GRM2 and schizophrenia: As shown in Table 8, the activity of the combined administration of sub-effective doses of an allosteric agonist of M1 or PAM of M5 receptors with sub-effective doses of PAMs of mGlu2 or GABAB receptors was observed in models of the cognitive symptoms of schizophrenia, but not in the models of positive symptoms [170].